Acute renal failure during interferon treatment

Drs I H FAHAL, N MURRY, P CHU, and G M BELL (Royal Liverpool University Hospital, Liverpool L7 8XP) write: Interferon alfa-2b is used as maintenance treatment in patients with multiple myeloma.¹ Although renal toxicity is rare, mild proteinuria is common.² We present the case of a patient who developed acute renal failure during treatment with recombinant interferon alfa-2b.

A 49 year old woman was admitted with a week's history of nausea, vomiting, and declining urinary output. Two years previously an IgG κ multiple myeloma had been diagnosed. Ten months before admission maintenance treatment with recombinant interferon alfa-2b (introna A) 3 MU was started subcutaneously thrice weekly. She took additionally only ferrous sulphate and vitamin B complex.

On admission she was pale and apyrexial, with a blood pressure of 120/70 mm Hg, a sinus tachycardia of 100 beats/min, and a central venous pressure of 1 mm H₂O. Cardiovascular, respiratory, and abdominal examination showed nothing abnormal. Investigations showed: serum sodium 127 mmol/l (normal 136-148), potassium 4.2 mmol/l (3.8-5.0), blood urea 26.8 mmol/l (2.5-6.6), and serum creatinine 1020 μ mol/l (62-124). Haemoglobin was 90 g/l, white cell count $11.8 \times 10^9/l$, platelet count $405 \times 10^9/l$, and erythrocyte sedimentation rate 130 mm in first hr, and plasma viscosity was raised (2.21 mPa.s). A coagulation screen gave normal results. Serum IgG was raised at 35 g/l (5-14), with a monoclonal IgG κ paraprotein. Repeated infection screens were negative. Urine examination revealed considerable protein (++) but no blood or myoglobin. Renal biopsy suggested severe tubular cell damage, but no tubular casts or myeloma and no amyloid deposits or urate crystals were seen.

Interferon was discontinued and the patient managed conservatively with dopamine and fluid restriction. Urine output gradually improved and she underwent a polyuric phase with resolution of her renal failure.

Mild proteinuria,³ the nephrotic syndrome,⁴ and acute interstitial nephritis⁵ have been reported in association with interferon alfa. Acute tubular necrosis in this patient was possibly a toxic effect of interferon as there was no other apparent cause. The renal biopsy excluded uric acid crystals or myeloma casts causing tubular obstruction, and there was no history of nephrotoxic drug ingestion or evidence of drug rashes or eosinophilia. Renal dysfunction is known to increase the toxicity of interferon

and adequate hydration is always necessary during treatment. Although the renal failure developed 10 months after the start of interferon treatment, mild dehydration secondary to vomiting might have triggered the nephrotoxicity reaction.

Interferon is used to treat haematological malignancies,^{1,2,6} and such adverse reactions as acute renal failure may be seen more frequently. Regular urine analysis, monitoring of fluid balance, and renal function are therefore advisable. Discontinuation should be urgently considered at early signs of renal impairment.

- Mandelli F, Giuseppe A, Amadori S, et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. *N Engl J Med* 1990;322:1430-4.
- Roth MS, Foon KA. Alpha interferon in the treatment of haematologic malignancies. *Am J Med* 1986;81:871-82.
- Quesada JR, Talpaz M, Rios A, Kurzock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. *J Clin Oncol* 1986;4:234-43.
- Selby P, Kohn J, Raymond J, Judson I, McElwain T. Nephrotic syndrome during treatment with interferon. *BMJ* 1985;290:1180.
- Averbuch SD, Austin HA III, Sherwin SA, Antonovych T, Bunn PA, Longo DL. Acute interstitial nephritis with the nephrotic syndrome following recombinant leucocyte A interferon therapy for mycosis fungoides. *N Engl J Med* 1984;310:32-5.
- Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Haematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. *N Engl J Med* 1986;314:1065-9.

Hypersensitivity vasculitis related to nicoumalone

Drs R SUSANO, A GARCIA, A ALTADILL, and J FERRO (Hospital Central de Asturias, 33006-Oviedo, Spain) write: Only certain allergic reactions, mainly bleeding due to depressed coagulation factors and microvascular thrombosis leading to necrosis, have so far been regarded as nicoumalone related skin reactions.^{1,4} We report a case of vasculitis, not previously presented in the classic literature^{5,7} or known to the Spanish drug surveillance programme.

A 74 year old white woman with bilateral varicose veins was admitted with deep venous thrombosis, pulmonary embolism, and arrhythmia. Levels of antithrombin III and protein C were normal, and she was negative for antiphospholipid antibodies. There was no indication of any neoplastic disorder. Heparin was prescribed and the patient was discharged after two weeks taking nicoumalone 2 mg/day, ranitidine, and amiodarone. Three weeks later she was readmitted with six day old palpable purpura in both legs with

no other clinical features. The prothrombin time was 18 seconds (control 12 seconds) and the partial thromboplastin time 35 seconds. The following investigations all gave normal findings: differential blood count, erythrocyte sedimentation rate, blood biochemistry, measurement of plasma protein complement, antistreptolysin O, urinary sediment, cryoglobulins, and latex and anti-nuclear antibodies. All drugs were stopped. A skin biopsy displayed features of leucocytoclastic vasculitis. She was given prophylactic heparin and steadily improved over 15 days. The skin lesions reappeared, however, a few hours after a single dose of nicoumalone 4 mg, and the patient was finally discharged taking just subcutaneous heparin. One year later she remained free of symptoms.

While the re-exposure suggests that nicoumalone caused the vasculitis, there remains a possibility that amiodarone—capable both of immune based alterations and of interference in the metabolism of these drugs, even months after its withdrawal—might have acted as a cofactor by an unknown mechanism.

- Koch-Weser J. Coumarin necrosis. *Ann Intern Med* 1968;68:1365-7.
- McGehee WG, Klotz TA, Epstein DJ, Rapaport SI. Coumarin necrosis associated with hereditary protein C deficiency. *Ann Intern Med* 1984;101:59-60.
- Levine MN, Hirsh J. Hemorrhagic complications of anticoagulant therapy. *Semin Thromb Hemost* 1986;12:39-57.
- Cole MS, Minifee PK, Wolma FJ. Coumarin necrosis: a review of the literature. *Surgery* 1988;103:271-7.
- Loeliger EA. Drugs affecting blood coagulation and hemostasis. In: Dukes MMG, Beeley L, eds. *Mayer's side effects of drugs*, annual 12. Amsterdam: Elsevier Science, 1988:309-15.
- Griffin JP, D'Arcy PF, Speirs CJ. Anticoagulants. In: Griffin JP, ed. *A manual of adverse drug interactions*. 4th ed. London: Wright, Butterworth, Heinemann, 1988:137-58.
- Magerus PW, Broze Jr GJ, Mietich JP, Tollefsen M. Anticoagulant, thrombolytic, and antiplatelet drugs. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. *Goodman and Gilman's the pharmacological basis of therapeutics*. 8th ed. New York: Pergamon Press, 1990:1311-31.

A new skin lesion associated with intravenous streptokinase

Drs J E SMITHSON, C T C KENNEDY, and S HUGHES (Southmead Hospital, Bristol BS10 5NB) write: We describe three patients with discrete purpuric papules following intravenous streptokinase dissimilar to skin lesions previously described.^{1,4} All three received aspirin 150-300 mg daily by mouth, intravenous streptokinase (1.5 MU), and subsequently heparin infusion for 24 hours.

Case 1—After admission a 66 year old smoker with confirmed anterior myocardial infarction developed five small non-blanching purple papules

on the dorsum of the right hand. No other rash was present and the lesions resolved spontaneously over several days. On admission the patient was taking timolol eye drops (0.25%), and he received one oral dose of atenolol 50 mg before the rash appeared.

Case 2—A 46 year old man with inactive ulcerative colitis and a confirmed anteroseptal infarct developed fever (39°C) and a painless dark blue-black papule on the dorsum of his left hand 24 hours after admission. The fever and skin lesion both resolved over 48 hours. There was no microscopic haematuria and subsequent lipid profile was normal. The patient was taking no medication on admission and no other drugs were administered before the appearance of the rash.

Case 3—A 75 year old woman with a confirmed inferior myocardial infarct developed a small papule on the dorsum of the right ring finger 24 hours after admission. Sections of the lesion stained with haematoxylin and eosin showed a subepidermal collection of neutrophils, red blood cells, and fibrin. Beneath this were superficial dermal venules showing endothelial cell swelling. Epithelial downgrowths at the periphery separated the collection of neutrophils and blood from the dermis. Complement and platelet aggregation studies were normal. On admission the patient was taking dothiepin 50 mg at night, and received one intravenous dose of diamorphine (5 mg) and metoclopramide (10 mg) shortly after admission.

In all three cases the platelet count was normal and activated partial thromboplastin time was in the therapeutic range in the two men. In the third case activated partial thromboplastin time was raised but there was no evidence of spontaneous bleeding.

Although the histology is consistent with vasculitis, the distribution would be unusual for vasculitis or emboli. Such lesions have not been described with aspirin, heparin or β blockers. These lesions do not appear to be clinically important and resolve spontaneously without scarring.

- Alexopoulos D, Raine AEG, Cobbe SM. Serum sickness complicating intravenous streptokinase therapy in acute myocardial infarction. *Eur Heart J* 1984;5:1010-2.
- Noel J, Rosenbaum LH, Gangadharan V, Stewart J, Galens G. Serum sickness-like illness and leukocytoclastic vasculitis following intra-coronary arterial streptokinase. *Am Heart J* 1987;113:395-7.
- Bucknall C, Darley C, Flax J, Vincent R, Chamberlain DA. Vasculitis complicating treatment with intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. *Br Heart J* 1988;59:9-11.
- Stafford PJ, Strachan CJL, Vincent R, Chamberlain DA. Multiple micro-emboli after disintegration of clot during thrombolysis for acute myocardial infarction. *BMJ* 1989;299:1310-2.